MedTrace Logo

Personalised Risk-based Breast Cancer Prevention and Screening

NCT03989258 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28389

Last updated 2019-06-20

No results posted yet for this study

Summary

This is a cohort study, applied research and T3 translational genomics to estimate the impact of genetic risk for breast cancer detection in the screening program. The study group base consists of 28 389 female participants, currently in the age-group 22-79, in the Biobank of Estonian Genome Centre. The study is aimed to demonstrate the usability of personalised approach for adjusting and stratifying screening recommendations, based on predicted genetic risk estimates for breast cancer in the situation, where the genome data could be available from all women who have given informed consent for that. The project includes both the detection of moderate and high hereditary breast cancer risk carriers as well as high risk polygenic risk-score (consisting several single nucleotide polymorphisms) carriers among healthy individuals for application of personalised prevention and screening strategies.

Conditions

Interventions

DIAGNOSTIC_TEST

Mammography outside official screening

Radiologic study

Sponsors & Collaborators

  • University of Tartu

    collaborator OTHER

  • North Estonia Medical Centre

    collaborator OTHER

  • Tartu University Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03989258 on ClinicalTrials.gov